American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2932-2947

  Kris, Mark G ^a   Hesketh, Paul J ^a   Somerfield, Mark R ^a   Feyer, Petra ^a   Clark Snow, Rebecca ^a   Koeller, James M ^a   Morrow, Gary R ^a   Chinnery, Lawrence W ^a   Chesney, Maurice J ^a   Gralla, Richard J ^a   Grunberg, Steven M ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; GRANISETRON; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PHENOTHIAZINE; PREDNISONE; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNINDEXED DRUG; VINCRISTINE;

AKATHISIA; AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DYSTONIA; HEADACHE; HUMAN; MEDICAL SOCIETY; META ANALYSIS; NAUSEA; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION INDUCED EMESIS; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; VOMITING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; NEOPLASM; RADIOTHERAPY;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; NAUSEA; NEOPLASMS; RADIOTHERAPY; VOMITING;

EID: 33745515076     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.9591     Document Type: Review

References (110)

1. Gralla RJ, Osoba D, Kris MG, et al: Clinical practice guidelines for the use of antiemetics: Evidence-based report by the American Society of Clinical Oncology. J Clin Oncol 17:2971-2994, 1999
2. Smith TJ, Somerfield MR: The ASCO experience with evidence-based clinical practice guidelines. Oncology (Williston Park) 11:223-227, 1997
3. Dando TM, Perry CM: Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777-797, 2004
4. 3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. http:/www.cancercare.on .ca/pdf/pebc12_3f.pdf
5. Ioannidis JP, Hesketh PJ, Lau J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 18:3409-3422, 2000
6. del Giglio A, Soares HP, Caparroz C, et al: Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Cancer 89:2301-2308, 2000
7. Jordan K, Hinke A, Grothey A, et al: Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: A pooled analysis. Support Care Cancer 13:26-31, 2005
8. Warr D, Oliver T, Members of the Systemic Treatment Disease Site Group: The role of Neurokinin-1 receptor antagonists in the prevention of emesis due to high-dose cisplatin: A clinical practice guideline. http:// www.cancercare.on.ca/pdf/pebc12-4f.pdf
9. Peterson K, McDonagh MS, Carson S, et al: Drug class review on newer Antiemetics, Final Report. http://www.ohsu.edu/drugeffectiveness/reports/ documents/Newer%20Antiemetics%20Final%20 Report.pdf
10. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28, 2006
11. Gralla RJ, Roila F, Tonato M: The 2004 Perugia Antiemetic Consensus Guideline process: Methods, procedures, and participants. Support Care Cancer 13:77-79, 2005
12. Grunberg SM, Osoba D, Hesketh PJ, et al: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: An update. Support Care Cancer 13:80-84, 2005
13. Kris MG, Hesketh PJ, Herrstedt J, et al: Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13: 85-96, 2005
14. Herrstedt J, Muss HB, Warr DG, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555, 2005
15. Tonato M, Clark-Snow RA, Osoba D, et al: Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13:109-111, 2005
16. Einhorn LH, Rapoport B, Koeller J, et al: Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: Review and consensus statement. Support Care Cancer 13:112-116, 2005
17. Aapro MS, Schmoll HJ, Poli-Bigelli S, et al: Comparison of aprepitant combination regimen with 4-day ondansetron + 4-day dexamethasone for prevention of acute and delayed nausea/vomiting after cisplatin chemotherapy. J Clin Oncol 23:730s, 2005 (suppl; abstr 8007)
18. Feyer P, Maranzano E, Molassiotis A, et al: Radiotherapy-induced nausea and vomiting (RINV): Antiemetic guidelines. Support Care Cancer 13:122-128, 2005
19. Roila F, Feyer P, Maranzano E, et al: Antiemetics in children receiving chemotherapy. Support Care Cancer 13:129-131, 2005 [Erratum: Support Care Cancer 13:132, 2005]
20. Roila F, Herrstedt J, Hesketh PJ: Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28, 2006
21. Aapro M: Methodological issues in antiemetic studies. Invest New Drugs 11:243-253, 1993
22. Gralla RJ, Clark RA, Kris MG, et al: Methodology in anti-emetic trials. Eur J Cancer 27:S5-S8, 1991
23. Fetting JH, Grochow LB, Folstein MF, et al: The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487-1493, 1982
24. Clark R, Tyson L, Frisone M: A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER). Oncol Nurs Forum 12:96, 1985 (suppl)
25. Lindley C, Bernard S, Fields SM: Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149, 1989
26. Hesketh PJ, Kris MG, Grunberg SM, et al: A proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997
27. Antiemetic Subcommittee: Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis - Results of the Perugia Consensus Conference. Ann Oncol 9:811-819, 1998
28. Gralla R, Lichinitser M, Van Der Vegt S, et al: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577, 2003
29. 3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482, 2003
30. Aapro M, Bertoli L, Lordick F, et al: Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supp Care Cancer 11:391, 2003 (abstr A17)
31. Italian Group for Antiemetic Research: Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16: 2937-2942, 1998
32. Italian Group for Antiemetic Research: Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:725-730, 2004
33. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003
34. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003
35. Warr DG, Grunberg SM, Gralla RJ, et al: The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278-1285, 2005
36. McCrea JB, Majumdar AK, Goldberg MR, et al: Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24, 2003
37. Navari RM, Reinhardt RR, Gralla RJ, et al: Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340: 190-195, 1999
38. Chawla SP, Grunberg SM, Gralla RJ, et al: Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290-2300, 2003
39. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005
40. Nygren P, Hande K, Petty KJ, et al: Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 55:609-616, 2005
41. de Jonge ME, Huitema AD, Holtkamp MJ, et al: Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 56:370-378, 2005
42. Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909, 1981
43. Jantunen IT, Kataja W, Muhonen TT: An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66-74, 1997
44. Hainsworth JD: The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 19:48-52, 1992
45. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies: Ondansetron Study Group. Am J Clin Oncol 17:137-146, 1994
46. Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384, 1985
47. Kris MG, Gralla RJ, Tyson LB, et al: Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114, 1989
48. Koo WH, Ang PT: Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71-74, 1996
49. Ossi M, Anderson E, Freeman A: 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 53:78-85, 1996 (suppl 1)
50. Kaizer L, Warr D, Hoskins P, et al: Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050-1057, 1994
51. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810-816, 1990
52. Kris MG, Radford J, Pizzo B, et al: Dose ranging antiemetic trial of the NK-1 receptor antagonist CP-122,721: A new approach for acute and delayed emesis following cisplatin. Proc Am Soc Clin Oncol 547, 1996 (abstr 1780)
53. Roila F: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5, 1995
54. Roila F, Boschetti E, Tonato M: Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone: A randomized single-blind study. Am J Clin Oncol 14:238-242, 1991
55. Lofters WS, Pater JL, Zee B, et al: Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966-2973, 1997
56. Navari R, Madajewicz S, Anderson N, et al: Oral ondansetron effectively controls cisplatin-induced delayed emesis. Proc Am Soc Clin Oncol 14:523, 1995 (abstr 1720)
57. Kris MG, Radford JE, Pizzo BA, et al: Use of a NK-1 receptor antagonist to prevent delayed emesis following cisplatin. J Natl Cancer Inst 89:817-818, 1997
58. Navari RM, Reinhardt RR, Gralla RJ, et al: Prevention of cisplatin-induced emesis by a neurokinin-1-receptor antagonist. N Engl J Med 340: 1927-1928, 1999
59. Gebbia V, Testa A, Valenza R, et al: Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Cancer 76: 1821-1828, 1995
60. Strum S, McDermed J, Abrahano-Umall R, et al: Management of cisplatin (DDP)-induced delayed-onset nausea (N) and vomiting (V): Preliminary results with 2 drug regimens. Proc Am Soc Clin Oncol 4:263, 1985
61. Johnston D, Latreille J, Laberge F, et al: Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP): A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Proc Am Soc Clin Oncol 14:529, 1995
62. Andrykowski MA, Redd WH, Hatfield AK: Development of anticipatory nausea: A prospective analysis. J Consult Clin Psychol 53:447-454, 1985
63. Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990
64. DeMulder PH, Seynaeve C. Vermorken JB, et al: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:834-840, 1990
65. Grunberg SM, Lane M, Lester EP, et al: Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 32:268-272, 1993
66. Tonato M, Roila F, Del Favero A: Methodology of antiemetic trials: A review. Ann Oncol 2:107-114, 1991
67. Gandara DR, Harvey WH, Monaghan GG, et al: The delayed-emesis syndrome from cisplatin: Phase III evaluation of ondansetron versus placebo. Semin Oncol 19:67-71, 1992
68. Kris MG, Pisters KMW, Hinkley L: Delayed emesis following anticancer chemotherapy. Support Care Cancer 2:297-300, 1994
69. Pater JL, Lofters WS, Zrr B, et al: The role of the 5HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181-185, 1997
70. Levitt M, Warr D, Yelle L, et al: Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 328:1081-1084, 1993
71. Aapro M, Selak M, Lichinitser D, et al: Palonosetron (PALO) is more effective than ondansetron (OND) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC): Results of a phase III trial. Proc Am Soc Clin Oncol 22:726, 2003 (abstr 2918)
72. Latreille J, Pater J, Johnston D, et al: Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174-1178, 1998
73. Roila F: Prevention of cisplatin-induced delayed emesis: Still unsatisfactory. Support Care Cancer 8:229-232, 1999
74. Gridelli C, lanniello GP, Ambrosini G, et al: A multicentre, double-blind, randomized trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. Int J Oncol 10:395-400, 1997
75. Italian Group for Antiemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559, 2000
76. Andrykowski MA, Jacobsen PB, Marks E, et al: Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607-2613, 1988
77. Burish TG, Carey MP: Conditioned aversive responses in cancer chemotherapy patients: Theoretical and developmental analysis. J Consult Clin Psychol 54:593-600, 1986
78. Morrow GR, Morrell C: Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307:1476-1480, 1982
79. Morrow GR: Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68:585-588, 1982
80. Morrow GR: Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 2:1170-1176, 1984
81. Morrow GR: Anticipatory nausea. Cancer Invest 6:327-328, 1988
82. Morrow GR, Lindke J, Black PM: Predicting development of anticipatory nausea in cancer patients: Prospective examination of eight clinical characteristics. J Pain Symptom Manage 6:215-223, 1991
83. Morrow GR, Rosenthal SN: Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53:4-7, 1996 (suppl 1)
84. Aapro MS, Kirchner V, Terrey JP: The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: The effect of granisetron. Br J Cancer 69:957-960, 1994
85. Alba E, Bastus R, de Andres L, et al: Anticipatory nausea and vomiting: Prevalence and predictors in chemotherapy patients. Oncology 46:26-30, 1989
86. Morrow GR: Chemotherapy-related nausea and vomiting: Etiology and management. CA Cancer J Clin 39:89-104, 1989
87. Fallowfield LJ: Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer 28A:S39-S41, 1992 (suppl 1)
88. White L, Daly SA, McKenna CJ, et al: A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens administered in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 17:445-455, 2000
89. Forni C, Loro L, Mazzei T, et al: Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of cisplatin-doxorubicin and high-dose ifosfamide over 48, 24, and 120 hours. Cancer Nurs 26:331-334, 2003
90. Jaing TH, Tsay PK, Hung IJ, et al: Single-dose oral granisetron versus imultidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatr Hematol Oncol 21:227-235, 2004
91. Coppes MJ, Lau R, Ingram LC, et al: Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Med Pediatr Oncol 33: 99-105, 1999
92. Coppes MJ, Yanofsky R, Pritchard S, et al: Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 21:274-283, 1999
93. Wada I, Takeda T, Sato M, et al: Pharmacokinetics of granisetron in adults and children with malignant diseases. Biol Pharm Bull 24:432-435, 2001
94. Sanchez LA, Holdsworth M, Bartel SB: Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis: Economic implications. Pharmacoeconomics 18:533-556, 2000
95. Tsuchida Y, Hayashi Y, Asami K, et al: Effects of granisetron in children undergoing high-dose chemotherapy: A multi-institutional, cross-over study. Int J Oncol 14:673-679, 1999
96. Allen JC, Gralla R, Reilly L, et al: Metoclopramide: Dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 3:1136-1141, 1985
97. Kris MG, Tyson LB, Gralla RJ, et al: Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309:433-434, 1983
98. Hunter AE, Prentice HG, Pothecary K, et al: Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 7:439-441, 1991
99. Prentice HG, Cunningham S, Gandhi L, et al: Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15:445-448, 1995
100. Tiley C, Powles R, Catalano J, et al: Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 7:317-321, 1992
101. Scarantino CW, Ornitz RD, Hoffman LG, et al: Radiation-induced emesis: Effects of ondansetron. Semin Oncol 19:38-43, 1992
102. Scarantino CW, Ornitz RD, Hoffman LG, et al: On the mechanism of radiation-induced emesis: The role of serotonin. Int J Radiat Oncol Biol Phys 30:825-830, 1994
103. Danjoux CE, Rider WD, Fitzpatrick PJ: The acute radiation syndrome: A memorial to William Michael Court-Brown. Clin Radiol 30:581-584, 1979
104. Lippens RJ, Broeders GC: Ondansetron in radiation therapy of brain tumor in children. Pediatr Hematol Oncol 13:247-252, 1996
105. Miralbell R, Coucke P, Behrouz F, et al: Nausea and vomiting in fractionated radiotherapy: A prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. Eur J Cancer 31A:1461-1464, 1995
106. Westbrook C, Glaholm J, Barrett A: Vomiting associated with whole body irradiation. Clin Radiol 38:263-266, 1987
107. Schwella N, Konig V, Schwerdtfeger R, et al: Ondansetron for efficient emesis control during total body irradiation. Bone Marrow Transplant 13:169-171, 1994
108. Priestman TJ, Roberts JT, Upadhyaya BK: A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 5:358-363, 1993
109. Franzen L, Nyman J, Hagberg H, et al: A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 7:587-592, 1996
110. Priestman SG, Priestman TJ, Canney PA: A double-blind randomised cross-over comparison of nabilone and metoclopramide in the control of radiation-induced nausea. Clin Radiol 38:543-544, 1987